FDA orders GLP-1 weight-loss drugs to carry blindness risk warnings
The US regulator mandates label updates for Ozempic, Wegovy and other medications after linking them to nonarteritic anterior ischemic optic neuropathy.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
First reported by STAT, 32 min ahead of the next publisher · who breaks stories first
The story so far
9 publishers have covered this in 18 articles since 9 Nov 2026. STAT published first, on 9 November at 15:56 UTC; MedPageToday.com - medical news for physicians followed 32 min later. The most recent article, from The Hill, appeared on 12 November at 15:30 UTC.
Outlets reporting it: News Feed (major outlet), The Hill (major outlet), The Guardian (major outlet), Ars Technica (major outlet), STAT, MedPageToday.com - medical news for physicians, MarketWatch, Quartz, BBC News.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- STATSTAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
- MedPageToday.com - medical news for physiciansFDA Slaps New Safety Warning on GLP-1 Drugs
- News FeedUS regulator orders makers of weight-loss drugs to carry blindness risk warning
- MarketWatchOzempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
- QuartzFDA is requiring weight loss drug makers to add a vision loss warning
- QuartzHow Ozempic and Zepbound are reshaping 10 industries
- QuartzBMI, health conditions and medical history decide GLP-1 weight-loss eligibility
- Quartz10 GLP-1 side effects: which are normal and which need a doctor
- The HillFDA warns of rare 'eye stroke' risk from GLP-1 drugs
- Quartz10 GLP-1 warning signs that mean you should call a doctor right away
Show 8 later sources
- Quartz15 GLP-1 side effects, from most to least likely, including rare vision loss
- The GuardianPharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
- STATSTAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more
- STATSTAT+: GLP-1s are given an FDA warning for rare eye condition risk
- Ars TechnicaGLP-1 drugs may increase risk of vision loss from rare condition, FDA warns
- BBC NewsMakers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
- The GuardianFDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
- The HillThe risk of blindness from GLP-1 drugs is too serious to ignore
Sources
Every article we clustered into this story. Headlines link to the publisher.
- The risk of blindness from GLP-1 drugs is too serious to ignore The Hill ·
- FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications The Guardian ·
- GLP-1 drugs may increase risk of vision loss from rare condition, FDA warns Ars Technica ·
- Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn The Guardian ·
- FDA warns of rare 'eye stroke' risk from GLP-1 drugs The Hill ·
- US regulator orders makers of weight-loss drugs to carry blindness risk warning News Feed ·
Show 12 more sources
- Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness BBC News
- STAT+: GLP-1s are given an FDA warning for rare eye condition risk STAT
- STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more STAT
- 15 GLP-1 side effects, from most to least likely, including rare vision loss Quartz
- 10 GLP-1 warning signs that mean you should call a doctor right away Quartz
- 10 GLP-1 side effects: which are normal and which need a doctor Quartz
- BMI, health conditions and medical history decide GLP-1 weight-loss eligibility Quartz
- How Ozempic and Zepbound are reshaping 10 industries Quartz
- FDA is requiring weight loss drug makers to add a vision loss warning Quartz
- Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss MarketWatch
- FDA Slaps New Safety Warning on GLP-1 Drugs MedPageToday.com - medical news for physicians
- STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition STAT
In this story
- FDA
- Novo Nordisk
- Eli Lilly
- Sanofi
- Ozempic
- Wegovy